A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
← catalyst calendarNCT05123482 · readout in 406 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
460estimated
Sites
67
Countries
Australia, Belgium, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-18 | actual | When the study began enrolling |
| Primary completion | 2027-09-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-29 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Biliary Tract Carcinoma
- Ovarian Cancer
- Endometrial Cancer
- Squamous Non-Small Cell Lung Cancer
Interventions
- Drug: AZD8205
- Drug: AZD8205 and AZD2936 (Rilvegostomig)
- Drug: AZD8205 and AZD5305 (saruparib)
- Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
- Drug: AZD8205 in combination with AZD9574
- Drug: AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
Primary outcomes
what the primary-completion date above is the date OFThe number of patients with adverse events
measured From time of Informed consent to 30 days post last dose (approximately 1 year).
The number of patients with serious adverse events
measured From time of Informed consent to 30 days post last dose (approximately 1 year)
The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.
measured From first dose of study treatment until the end of Cycle 1 (approximately 21 days).
The number of patients with changes from baseline laboratory findings, ECGs and vital signs
measured From time of informed consent to 30 days post last dose (approximately 1 year)
Publications
- PMID 39392424 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed